Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...

The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.

Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...

Shares of Amgen Inc. AMGN advanced 1.99% to $319.10 Thursday, on what proved to be an all-around great trading session for ...

Amgen said on Tuesday that its drug helped improve daily activities including chewing and swallowing in patients suffering ...

Cantor initiated Amgen (AMGN) coverage with an overweight rating, asserting it was a “big believer” in the biotech company’s ...

Federman & Sherwood investigates Amgen, Inc. for data breach. Amgen became aware of a cybersecurity incident that involved one of their service providers, Sirva Relocation, LLC and its parent company ...

Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...

Amgen (AMGN) ended the recent trading session at $322.67, demonstrating a +1.12% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.13%.

On 4, 2024, Amgen, Inc. filed a notice of data breach with the Attorney General of Massachusetts after discovering that ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $326.38, a high estimate of $381 ...

In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab and Uplizna ...